Until this time, no studies had evaluated the safety and effectiveness of rasburicase in Chinese pediatric patients with non-Hodgkin’s lymphoma (NHL) and acute leukemia (AL).

The current study evaluated the safety and effectiveness of rasburicase in Chinese pediatric patients with NHL and AL and demonstrated tolerable safety and efficacy.

Being the first study to evaluate the safety and effectiveness of rasburicase in Chinese pediatric patients, the current study offers a new option in the treatment armamentarium for hematological malignancies having a risk of tumor lysis syndrome.